Miguel Abboud to Platelet Aggregation Inhibitors
This is a "connection" page, showing publications Miguel Abboud has written about Platelet Aggregation Inhibitors.
Connection Strength
0.566
-
Pharmacokinetics and safety of ticagrelor in infants and toddlers with sickle cell disease aged <24?months. Pediatr Blood Cancer. 2021 05; 68(5):e28977.
Score: 0.152
-
Ticagrelor versus placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: Rationale and design of a randomized, double-blind, parallel-group, multicenter phase 3 study (HESTIA3). Contemp Clin Trials. 2019 10; 85:105835.
Score: 0.137
-
Ticagrelor does not impact patient-reported pain in young adults with sickle cell disease: a multicentre, randomised phase IIb study. Br J Haematol. 2019 01; 184(2):269-278.
Score: 0.130
-
A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events. N Engl J Med. 2016 Feb 18; 374(7):625-35.
Score: 0.106
-
Ticagrelor vs placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: the HESTIA3 study. Blood. 2022 09 29; 140(13):1470-1481.
Score: 0.042